These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33813432)

  • 21. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
    Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Pfiffer T; Hatano E; Chung HC; Kopeckova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Hsu Y; Abada PB; Zhu AX
    Br J Cancer; 2018 Jul; 119(1):19-26. PubMed ID: 29808014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
    J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
    Turkes F; Chau I
    Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
    Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
    Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
    Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Ikeda M; Callies S; McGrath LM; Wang C; Abada P; Widau RC; Gonzalez-Gugel E; Zhu AX
    Clin Cancer Res; 2022 Jun; 28(11):2297-2305. PubMed ID: 35247922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2089-2093. PubMed ID: 32234901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
    Zhu AX; Finn RS; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Motomura K; Ohno I; Daniele B; Vogel A; Yamashita T; Hsu CH; Gerken G; Bilbruck J; Hsu Y; Liang K; Widau RC; Wang C; Abada P; Kudo M
    Br J Cancer; 2021 Apr; 124(8):1388-1397. PubMed ID: 33531690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
    Zhu AX; Nipp RD; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Wang C; Hsu Y; Abada PB; Kudo M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein.
    Yen CC; Yen CJ
    Expert Opin Drug Saf; 2022 Feb; 21(2):157-166. PubMed ID: 34668832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
    Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
    Negri F; Gnetti L; Pedrazzi G; Silini EM; Porta C
    Future Oncol; 2021 Sep; 17(27):3579-3584. PubMed ID: 34155918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
    Kanogawa N; Ogasawara S; Maruta S; Iino Y; Obu M; Ishino T; Ogawa K; Yumita S; Iwanaga T; Unozawa H; Nakagawa M; Fujiwara K; Sakuma T; Fujita N; Kojima R; Kanzaki H; Koroki K; Kobayashi K; Inoue M; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Koma Y; Azemoto R; Kato J; Kato N
    BMC Gastroenterol; 2023 Mar; 23(1):70. PubMed ID: 36906542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
    Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
    Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
    Reig M; Galle PR; Kudo M; Finn R; Llovet JM; Metti AL; Schelman WR; Liang K; Wang C; Widau RC; Abada P; Zhu AX
    Liver Int; 2021 Mar; 41(3):598-607. PubMed ID: 33188713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.